Strutton DR - Search Results

1

Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States.

Ray GT, Pelton SI, Klugman KP, Strutton DR, Moore MR. Ray GT, et al. Among authors: strutton dr. Vaccine. 2009 Nov 5;27(47):6483-94. doi: 10.1016/j.vaccine.2009.08.045. Epub 2009 Aug 29. Vaccine. 2009. PMID: 19720366

2

Modeling the decline in pneumococcal acute otitis media following the introduction of pneumococcal conjugate vaccines in the US.

Shea KM, Weycker D, Stevenson AE, Strutton DR, Pelton SI. Shea KM, et al. Among authors: strutton dr. Vaccine. 2011 Oct 19;29(45):8042-8. doi: 10.1016/j.vaccine.2011.08.057. Epub 2011 Aug 24. Vaccine. 2011. PMID: 21871518

3

Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada.

Earnshaw SR, McDade CL, Zanotti G, Farkouh RA, Strutton D. Earnshaw SR, et al. BMC Infect Dis. 2012 Apr 24;12:101. doi: 10.1186/1471-2334-12-101. BMC Infect Dis. 2012. PMID: 22530841 Free PMC article.

4

Reply to: economic evaluation of second generation pneumococcal conjugate vaccines in Norway.

Farkouh R, Klok R, Roberts C, Mack A, Strutton D. Farkouh R, et al. Vaccine. 2013 Jan 7;31(3):439-41. doi: 10.1016/j.vaccine.2012.03.012. Epub 2012 Mar 17. Vaccine. 2013. PMID: 22433959 No abstract available.

5

[Economic evaluation of an infant immunization program in Mexico, based on 13-valent pneumococcal conjugated vaccines].

Muciño-Ortega E, Mould-Quevedo JF, Farkouh R, Strutton D. Muciño-Ortega E, et al. Value Health. 2011 Jul-Aug;14(5 Suppl 1):S65-70. doi: 10.1016/j.jval.2011.05.025. Value Health. 2011. PMID: 21839902 Spanish.

6

Response to "Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries".

Strutton D, Hwang S, Farkouh R, Roberts C. Strutton D, et al. Vaccine. 2011 Oct 13;29(44):7589-90; author reply 7591-2. doi: 10.1016/j.vaccine.2011.02.103. Epub 2011 Mar 12. Vaccine. 2011. PMID: 21406264

7

7-Valent pneumococcal conjugate vaccine and lower respiratory tract infections: effectiveness of a 2-dose versus 3-dose primary series.

Pelton SI, Weycker D, Klein JO, Strutton D, Ciuryla V, Oster G. Pelton SI, et al. Vaccine. 2010 Feb 10;28(6):1575-82. doi: 10.1016/j.vaccine.2009.11.053. Epub 2009 Dec 8. Vaccine. 2010. PMID: 20003928

8

Clinical and economic burden of pneumococcal disease in older US adults.

Weycker D, Strutton D, Edelsberg J, Sato R, Jackson LA. Weycker D, et al. Vaccine. 2010 Jul 12;28(31):4955-60. doi: 10.1016/j.vaccine.2010.05.030. Epub 2010 May 22. Vaccine. 2010. PMID: 20576535

9

Cost-effectiveness of adult pneumococcal vaccination: response to Grabenstein et al.

Weycker D, Sato R, Strutton D, Edelsberg J, Atwood M, Jackson LA. Weycker D, et al. Vaccine. 2013 Apr 19;31(17):2109. doi: 10.1016/j.vaccine.2013.01.008. Epub 2013 Jan 11. Vaccine. 2013. PMID: 23318148 No abstract available.

10

Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years.

Weycker D, Sato R, Strutton D, Edelsberg J, Atwood M, Jackson LA. Weycker D, et al. Vaccine. 2012 Aug 3;30(36):5437-44. doi: 10.1016/j.vaccine.2012.05.076. Epub 2012 Jun 20. Vaccine. 2012. PMID: 22728289

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results